Almac Group Opens Additional Companion Diagnostic Laboratory in Durham NC USA

Almac Group Opens Additional Companion Diagnostic Laboratory in Durham NC USA

March 8, 2016

Craigavon, N.I., UK, – 08 March 2016 Almac Group’s Diagnostics Business Unit today announced the opening of their new companion diagnostic development facility located in the Research Triangle Park region of North Carolina, USA. The North Carolina facility will provide a US base to support Almac’s increased demand for its CDx development partnerships as well as a CLIA-accredited laboratory to support the downstream delivery of assays for patient testing.

Along with headquarters in Europe and partnerships in Asia, the new facility in the US will provide Almac Diagnostics with a strong global presence to continue to meet increasing customer demand and to support their growing client base.

The custom designed facility is located amongst one of the most prominent high-tech research and development centres in the world and contains molecular biology laboratories as well as office space. The state of the art laboratory is equipped with microarray and qPCR platforms appropriate for companion diagnostic development and will operate both research-use-only and clinical diagnostic tests. Plans are also in place to add additional technology platforms including NGS in the coming year.

‘The opening of our new CDx facility in the US is Almac Diagnostics’ latest initiative to better serve our global Biopharma partners. As we experience increased client demand for our companion diagnostic development services, this latest expansion will significantly enhance Almac’s offering, increasing capacity and further demonstrating our commitment to personalised healthcare’ said Professor Paul Harkin, President and Managing Director of Almac Diagnostics.

About Almac Group

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

Almac Diagnostics is one of six business units operating under the ownership of the Almac Group.  The global company partners with the biopharmaceutical industry supporting the discovery, development and delivery of companion diagnostics. In addition, Almac Diagnostics has a pipeline of proprietary oncology based tests in development in therapeutic areas including breast, colon, ovarian, prostate and lung cancer.

For more information visit or e-mail

FacebookTwitterLinkedInCopy Link

More news

  • October 24, 2018

    TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing, Pan-Cancer Companion Diagnostic

  • October 19, 2018

    Almac Group Launches claraT – A Unique, Software-driven Gene Expression Report

  • October 11, 2018

    Almac Group Invests in Cutting Edge Next Generation Sequencing Capabilities for Bio Pharma Clients

Back to news